TCWP’s CRISPR Therapeutics CRSP Stock Holding History

TCWP’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-230	Closed	-$14K	–	617
2022 Q1	$14K	Buy	+230	New	+$14.4K	﹤0.01%	787

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

TCWP's CRSP Position: Q2 2022 in Review

TCWP sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 230 shares — an estimated $14K sold.

TCWP first reported a position in CRSP in Q1 2022 and held it in 1 quarter. The position peaked at $14K in Q1 2022. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

TCWP reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
TCWP sold 230 CRISPR Therapeutics shares in Q2 2022, an estimated $14K.
TCWP first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 1 quarter.
TCWP's CRISPR Therapeutics position peaked at $14K in Q1 2022.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.